Clinical Trial

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Name: Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — clinical trial record (NCT07290569)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EVERLAST-B

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Protocol Amendment History 1 change

notable Trial sites expanded: 26 -> 36 locations 2026-06-03

Trial Details

NCT Number	NCT07290569
Lead Sponsor	Oruka Therapeutics, Inc.
Conditions	Plaque Psoriasis
Enrollment	160 participants
Start Date	2025-12-03
Primary Completion	2027-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-01